Skip to main content

Table 1 Variables associated with early tumor recurrence after hepatectomy for HCC (N = 144)

From: DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation

VariableRecurrencea
Univariate analysis
P value
Multivariate analysis
P valueHazard ratio95% confidence interval
Gender (male vs. female)0.154
Age, years (<  55 vs. ≥ 55)0.707
HBV (yes vs. no)0.540
HCV (yes vs. no)0.647
Bilirubin, mg/dL (<  1.2 vs. ≥ 1.2)0.863
Albumin, g/dL (< 3.5 vs. ≥ 3.5)0.252
ALT, U/L (<  35 vs. ≥ 35)0.207
PT, INR (<  1.2 vs. ≥ 1.2)0.0750.1042.8270.808–9.885
ICG, retention rate (<  15% vs. ≥ 15%)0.170
TNM stage (T1/2 vs. T3/4)0.417
Multiple tumors (yes vs. no)0.739
Child-Pugh class (A vs. B)0.251
Complete tumor capsule (yes vs. no)0.0510.0810.4180.157–1.112
Microvascular invasion (yes vs. no)0.001b0.3981.4680.603–3.578
Macrovascular invasion (yes vs. no)< 0.001b0.002b11.9932.553–56.339
Cut margin free (yes vs. no)0.873
Differentiation grade (1/2 vs. 3/4)0.168
Tumor size, cm (<  3 vs. ≥ 3)0.039b0.5540.7880.359–1.733
Satellite nodules (yes vs. no)0.008b0.9691.0190.393–2.640
AFP, ng/mL (<  400 vs. ≥400)0.625
Serum IL-6, ng/mL (<  150 vs. ≥ 150)0.023b0.0881.8960.910–3.949
Serum TGF-β (<  14,000 vs. ≥ 14,000)0.682
DNMT1 (< 2X vs. ≥ 2X)0.010b0.7191.1440.550–2.378
DNMT3a (< 2X vs. ≥ 2X)0.3050.2391.6320.722–3.689
DNMT3b (< 2X vs. ≥ 2X)0.037b0.1991.7790.739–4.285
OCT4 (< 2X vs. ≥ 2X)0.026b0.0851.9900.909–4.357
NANOG (< 2X vs. ≥ 2X)0.004b0.010b3.0741.309–7.220
High expression of OCT4 and DNMT3b (< 2X vs. ≥ 2X)0.001b0.3951.4840.597–3.685
High expression of OCT4 and DNMT1 (< 2X vs. ≥ 2X)0.013b0.2261.7540.705–4.364
  1. Abbreviations: AFP serum α-fetoprotein, ALT alanine aminotransferase, ICG indocyanine green, PT prothrombin time, INR international normalized ratio, Tumor size, the largest one if multiple
  2. aTime to early recurrence (less than 2 years)
  3. bP < 0.05.